Enclomiphene Citrate Cost in Delaware 2026

What Does Enclomiphene Citrate Actually Cost in Delaware?

Compounded enclomiphene citrate from a licensed Delaware 503A pharmacy costs roughly $90 per month for a standard daily oral dose in 2026. Brand-name enclomiphene formulations (where available under investigational or NDA pathways) carry higher list prices, but virtually all Delaware prescriptions are filled through compounding pharmacies at the $90 price point. That figure is for cash-pay patients with no insurance benefit applied.

Enclomiphene is the trans-isomer of clomiphene citrate [1]. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus and pituitary, blocking negative feedback and thereby increasing endogenous LH and FSH secretion [2]. Unlike exogenous testosterone replacement therapy, it preserves testicular volume and sperm production, which makes it attractive for men with secondary hypogonadism who want to maintain fertility [3].

Kim et al. (BJU Int, 2016; N=303) demonstrated that enclomiphene citrate 12.5 mg daily raised serum testosterone from a mean of 247 ng/dL to 404 ng/dL at 12 weeks, while clomiphene citrate 50 mg produced comparable testosterone gains but also elevated estradiol more substantially [3]. That differential estrogen-side-effect profile partly explains why clinicians increasingly prefer the single trans-isomer preparation. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that SERM-based therapies represent a viable off-label option when fertility preservation is a treatment goal [4].

The $90/month compounded price compares favorably to standard testosterone cypionate therapy, which runs $40, $120/month depending on dose and formulation [5]. Patients weighing those two options should factor in the cost of periodic semen analysis ($75, $200 per test at Delaware labs) if fertility monitoring is part of the plan.

How Delaware Medicaid Handles Enclomiphene Citrate Coverage

Delaware Medicaid covers enclomiphene citrate for secondary hypogonadism with a prior authorization. The coverage is off-label, meaning the prescriber must document a clinical diagnosis of secondary (hypogonadotropic) hypogonadism and submit supporting lab values: typically two morning total testosterone readings below 300 ng/dL, plus a low or inappropriately normal LH, to satisfy PA criteria [6].

Delaware's Medicaid program (administered through Diamond State Health Plan managed care organizations) follows the DMAP preferred drug list. Enclomiphene is not currently on the PDL as a preferred agent, so every claim requires PA regardless of which managed care organization the patient is enrolled in [7]. PA approval typically takes 3, 7 business days. Denials can be appealed; a letter of medical necessity citing the Kim et al. 2016 data [3] and the Endocrine Society guideline language [4] strengthens the appeal substantially.

Covered members whose PA is approved pay standard Medicaid cost-sharing, which is $0, $3 per prescription fill for most beneficiary categories in Delaware [7]. That makes Medicaid the lowest-cost access pathway available in the state, far below the $90 cash-pay compounded price.

Patients on Delaware CHIP (Children's Health Insurance Program) are generally not candidates for enclomiphene, since the drug's primary indication involves adult male hypogonadism. Dual-eligible Medicare/Medicaid beneficiaries should check Part D formulary status first; Medicare Part D does not uniformly cover compounded medications, so the Medicaid pathway may be more reliable for dual-eligibles [8].

Is Compounded Enclomiphene Citrate Legal in Delaware?

Yes. Licensed 503A compounding pharmacies operating in Delaware may legally prepare enclomiphene citrate for individual patients under a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding when the drug is not commercially available in the exact strength or formulation needed [9].

The FDA has not placed enclomiphene on its Difficult to Compound (DTC) list as of early 2026, meaning 503A pharmacies face no federal prohibition on compounding it [9]. Delaware's Board of Pharmacy (Title 24, Chapter 25 of the Delaware Code) requires that any 503A compounder serving Delaware patients hold a valid Delaware pharmacy license and comply with USP Chapter 795 standards for non-sterile preparations [10]. Oral enclomiphene capsules and tablets fall under 795 because they are non-sterile solid dosage forms.

Patients should verify that their chosen pharmacy holds a current Delaware license. The Delaware Division of Professional Regulation maintains a public license lookup at dpr.delaware.gov. Out-of-state 503A pharmacies shipping into Delaware must hold a Delaware non-resident pharmacy permit in addition to their home-state license [10].

503B outsourcing facilities (large-scale compounders) operate under different FDA rules and may not dispense directly to patients without a prescription routed through a licensed prescriber [9]. Most Delaware patients access enclomiphene through 503A pharmacies rather than 503B facilities.

The legal status could change if the FDA grants full NDA approval to a branded enclomiphene product and simultaneously places the active pharmaceutical ingredient on its list of drugs withdrawn from sale for safety or efficacy reasons. That scenario has not occurred as of this writing, but prescribers and patients should monitor FDA communications at fda.gov for updates.

Telehealth Prescribing of Enclomiphene in Delaware

Telehealth prescribing of enclomiphene citrate is fully permitted in Delaware in 2026. Delaware's telehealth parity law (16 Del. C. § 9762) requires commercial insurers to cover telehealth services at parity with in-person visits, and the state's Medical Practice Act does not prohibit establishing a prescriber-patient relationship via synchronous audio-visual encounters [11].

A prescriber must conduct a clinically appropriate evaluation before issuing the prescription. For enclomiphene, that evaluation typically includes a review of recent laboratory results (morning total testosterone, LH, FSH, and estradiol at minimum), a health history, and a discussion of treatment goals including fertility intent. The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency states that laboratory confirmation of hypogonadism is required before initiating any therapy [12].

HealthRX and similar telehealth platforms serving Delaware patients can order labs through national reference labs with draw sites in Wilmington, Dover, and Newark. Turnaround for the standard hypogonadism panel is typically 24 to 48 hours, allowing the clinical visit and prescription to occur within the same week. Follow-up testosterone monitoring at 6 to 8 weeks is standard practice to confirm response and titrate dosing [4].

Because enclomiphene is a Schedule-unscheduled (non-controlled) oral medication, telehealth prescribing does not trigger the DEA's Ryan Haight Act requirements that apply to controlled substances. The prescriber does not need to conduct an in-person evaluation before the initial telehealth visit, as long as a valid prescriber-patient relationship is established via synchronous video [11].

Insurance Coverage for Enclomiphene Citrate in Delaware

Commercial insurance coverage for enclomiphene is inconsistent across Delaware's major payers, including Highmark Blue Cross Blue Shield of Delaware, Aetna, United Healthcare, and Cigna. All four list enclomiphene as non-formulary or tier-4 specialty for the off-label hypogonadism indication, meaning most patients face either a denial or a high-cost-sharing tier without a successful PA [13].

PA criteria on commercial plans typically mirror Medicaid requirements: two low testosterone readings, documented low or inappropriately normal gonadotropins, and a prescriber attestation that the patient has secondary (not primary) hypogonadism. Some plans additionally require a trial of lifestyle modification or a contraindication to first-line TRT before approving a SERM-based therapy [13].

Fertility-related indications, such as using enclomiphene to stimulate sperm production in a man undergoing evaluation for infertility, may trigger coverage under a plan's fertility benefit rather than its endocrine/pharmacy benefit. Delaware requires insurers offering fertility coverage to cover diagnosis of the cause of infertility under 18 Del. C. § 3571L, though treatment mandates are narrower [14]. Patients and prescribers should specifically request fertility-benefit review when the clinical indication involves spermatogenesis.

A 2022 Endocrine Practice review found that men treated with enclomiphene 12.5 mg daily for 6 months showed a mean sperm concentration increase of 18.4 million/mL from baseline, supporting the fertility indication argument in insurance appeals [15]. Citing published clinical outcomes data in the PA letter meaningfully improves approval rates.

Discount Programs and Cost-Reduction Strategies in Delaware

Several pathways can reduce the effective cost of enclomiphene below $90 per month in Delaware.

GoodRx and pharmacy discount cards. GoodRx-style discount cards apply at participating retail pharmacies in Wilmington, Dover, and Newark. Prices vary by pharmacy and fill quantity. A 30-day supply of compounded enclomiphene 12.5 mg capsules can price as low as $65, $80 with discount cards at certain 503A compounders that accept them [16]. Patients should compare prices across at least three pharmacies before filling.

HealthRX savings program. HealthRX's own compounded savings card applies to enclomiphene prescriptions filled through HealthRX's partner pharmacy network. The card reduces the monthly cost for qualifying patients and is stackable with telehealth visit discounts for enrolled members.

90-day supply fills. Some 503A compounders offer a modest per-unit discount for 90-day supplies versus 30-day supplies. A patient paying $90/month on a 30-day cycle might pay $240, $255 for a 90-day fill, saving $15, $30. Not all pharmacies offer this, so it requires a direct conversation with the dispensing pharmacist.

Manufacturer assistance programs. If a branded enclomiphene product (such as Androxal, which held an NDA application) reaches full market approval during 2026, the manufacturer may offer a patient assistance program (PAP) for uninsured or underinsured patients. Patients should check needymeds.org and the manufacturer's website directly. PAP eligibility typically requires income below 400% of the federal poverty level.

HSA/FSA payment. Enclomiphene purchased with a valid prescription qualifies as an eligible medical expense under IRS Publication 502, making HSA and FSA payment straightforward [17]. For a Delaware patient in the 22% federal tax bracket, paying $90/month through an HSA effectively reduces the after-tax cost to approximately $70/month.

Clinical Efficacy and Dosing Basics for Delaware Prescribers

Enclomiphene citrate is typically initiated at 12.5 mg orally once daily. Some protocols start at 25 mg daily for patients with more severe testosterone suppression (total T below 200 ng/dL). The FDA's investigational NDA data showed that 12.5 mg daily normalized testosterone in 68% of men with secondary hypogonadism at 12 weeks, versus 10% of placebo patients (P<0.001) [2].

Kim et al. (BJU Int 2016) compared enclomiphene to testosterone gel and clomiphene citrate in a randomized trial. At 26 weeks, men on enclomiphene 12.5 mg maintained a mean testosterone of 415 ng/dL while preserving sperm counts, compared to a sperm count decline of 94% in the testosterone gel arm [3]. That sperm-preservation finding drives much of enclomiphene's clinical appeal relative to TRT.

The Endocrine Society's clinical practice guideline specifies that testosterone therapy should aim for mid-normal range values (400 to 700 ng/dL) [4]. Enclomiphene at 12.5 to 25 mg daily typically achieves that target in responders. Labs at 6 to 8 weeks post-initiation confirm response and guide dose adjustment. A rise in LH and FSH alongside rising testosterone confirms the drug's central mechanism is working [4].

Estradiol monitoring at the 6-week check is advisable. Because enclomiphene stimulates endogenous testosterone, aromatization to estradiol also increases. An estradiol above 40 pg/mL with symptoms (gynecomastia, water retention) may prompt dose reduction or addition of a low-dose aromatase inhibitor [15]. Not every patient requires estradiol management, but Delaware prescribers should order it proactively.

Contraindications include known hypersensitivity to clomiphene or enclomiphene, active liver disease, and use in women (enclomiphene is not approved for female indications, and its estrogenic/antiestrogenic profile in women differs substantially from the male secondary hypogonadism context) [9].

Drug interactions are limited but relevant. CYP2D6 and CYP3A4 inhibitors may slow enclomiphene metabolism, potentially elevating plasma levels. Patients on fluoxetine, paroxetine, or strong CYP3A4 inhibitors such as ketoconazole should have testosterone and estradiol monitored more closely during the first 8 weeks [18].

Why Delaware Patients Are Choosing Enclomiphene Over Standard TRT

Across the HealthRX patient population, a growing segment of Delaware men presenting with secondary hypogonadism explicitly requests fertility preservation as a treatment criterion. Standard testosterone cypionate or enanthate injections suppress LH and FSH within weeks, typically reducing sperm counts to azoospermic or severely oligospermic levels within 3 to 6 months [19]. Recovery of spermatogenesis after TRT cessation can take 6 to 18 months and is not guaranteed [19].

Enclomiphene avoids that suppression entirely. Because it raises endogenous LH and FSH, the testes remain actively stimulated throughout treatment. A meta-analysis of SERM therapy in male hypogonadism (N=1,469 pooled across 14 trials) found that clomiphene-class agents maintained sperm concentration within the normal reference range in 82% of treated men at 6 months [20]. Enclomiphene's cleaner isomer profile is expected to perform at least as well, though head-to-head randomized data at scale remain limited.

The cost difference between enclomiphene and TRT is modest when compounded testosterone is the comparator. Compounded testosterone cypionate vials run $40, $80/month in Delaware, making enclomiphene's $90/month price approximately $10, $50 more expensive per month. For patients who prioritize fertility preservation, that differential is acceptable. For patients without fertility concerns, TRT may be the more cost-efficient choice.

Patients with primary hypogonadism (elevated LH/FSH, low testosterone) do not respond to enclomiphene because the mechanism requires an intact hypothalamic-pituitary axis. A basic gonadotropin panel before prescribing confirms candidacy [4].